Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

William R Lagor

Showing results (1-10 of 62) with videos related to

Pageof 7
Sort By:
Current Atherosclerosis Reports|March 1, 2022
Treating Cardiovascular Disease with Liver Genome EngineeringAyrea Hurley, William R Lagor
Current Opinion in Lipidology|March 21, 2019
CRISPR: a promising tool for lipid physiology and therapeuticsMia Furgurson, William R Lagor
Methodist Debakey Cardiovascular Journal|May 4, 2019
Gene Delivery in Lipid Research and TherapiesMarco De Giorgi, William R Lagor
Journal of Inherited Metabolic Disease|May 31, 2023
Liver directed adeno-associated viral vectors to treat metabolic diseaseMarcel A Chuecos, William R Lagor
Current Opinion in Cardiology|February 20, 2020
Recent advances in genome editing for cardiovascular diseaseAlexandria M Doerfler, Christopher J Walkey, William R Lagor
The Journal of Biological Chemistry|August 30, 2005
Diabetes alters the occupancy of the hepatic 3-hydroxy-3-methylglutaryl-CoA reductase promoterWilliam R Lagor, Eric D de Groh, Gene C Ness
Experimental Biology and Medicine (Maywood, N.J.)|March 1, 2007
Functional analysis of the hepatic HMG-CoA reductase promoter by in vivo electroporationWilliam R Lagor, Richard Heller, Eric D de Groh, et al.
Biochemical and Biophysical Research Communications|May 19, 2004
Identification of insulin-responsive regions in the HMG-CoA reductase promoterAaron R Osborne, Veronica V Pollock, William R Lagor, et al.
Gut|May 11, 2017
CRISPR/Cas9: at the cutting edge of hepatologyFrancis P Pankowicz, Kelsey E Jarrett, William R Lagor, et al.
Molecular Therapy. Nucleic Acids|September 19, 2024
Simple improvements in vector design afford substantial gains in AAV delivery of aggregation-slowing Aβ variantsElla Borgenheimer, Cameron Trueblood, Bryan L Nguyen, et al.
Pageof 7

Showing results (1-10 of 62) with videos related to

Sort By:
Pageof 7
Current Atherosclerosis Reports|March 1, 2022
Treating Cardiovascular Disease with Liver Genome EngineeringAyrea Hurley, William R Lagor
Current Opinion in Lipidology|March 21, 2019
CRISPR: a promising tool for lipid physiology and therapeuticsMia Furgurson, William R Lagor
Methodist Debakey Cardiovascular Journal|May 4, 2019
Gene Delivery in Lipid Research and TherapiesMarco De Giorgi, William R Lagor
Journal of Inherited Metabolic Disease|May 31, 2023
Liver directed adeno-associated viral vectors to treat metabolic diseaseMarcel A Chuecos, William R Lagor
Current Opinion in Cardiology|February 20, 2020
Recent advances in genome editing for cardiovascular diseaseAlexandria M Doerfler, Christopher J Walkey, William R Lagor
The Journal of Biological Chemistry|August 30, 2005
Diabetes alters the occupancy of the hepatic 3-hydroxy-3-methylglutaryl-CoA reductase promoterWilliam R Lagor, Eric D de Groh, Gene C Ness
Experimental Biology and Medicine (Maywood, N.J.)|March 1, 2007
Functional analysis of the hepatic HMG-CoA reductase promoter by in vivo electroporationWilliam R Lagor, Richard Heller, Eric D de Groh, et al.
Biochemical and Biophysical Research Communications|May 19, 2004
Identification of insulin-responsive regions in the HMG-CoA reductase promoterAaron R Osborne, Veronica V Pollock, William R Lagor, et al.
Gut|May 11, 2017
CRISPR/Cas9: at the cutting edge of hepatologyFrancis P Pankowicz, Kelsey E Jarrett, William R Lagor, et al.
Molecular Therapy. Nucleic Acids|September 19, 2024
Simple improvements in vector design afford substantial gains in AAV delivery of aggregation-slowing Aβ variantsElla Borgenheimer, Cameron Trueblood, Bryan L Nguyen, et al.
Pageof 7